Clinica Doctor Balcangiu-Stroescu

Collagen Biostimulators: what they are, how they work, and what to expect

Collagen Biostimulators: what they are, how they work, and what to expect
Useful information
March 29, 2026Gabriel-Cosmin Balcangiu-Stroescu

Collagen biostimulators are modern injectable treatments used in aesthetic medicine to stimulate natural collagen production and improve skin firmness.

Unlike hyaluronic acid, which provides immediate volume, biostimulators work over time, regenerating the skin from within.

What are collagen biostimulators

Biostimulators are injectable substances that:

  • stimulate collagen production
  • improve skin elasticity
  • restore tissue firmness and structure

👉 They do not directly "fill" wrinkles, but rather cause the skin to regenerate naturally at its own pace.

Types of biostimulators

The most commonly used are:

  • polylactic acid (PLLA)
  • calcium hydroxyapatite (CaHA)
  • polynucleotides (in some cases)

👉 Each has different indications and mechanisms.

How it works

After injection:

  • the substance stimulates fibroblasts
  • collagen production increases
  • the skin becomes firmer and more elastic

👉 Results appear progressively, over several weeks or months.

What they are recommended for

Biostimulators are effective for:

  • skin laxity
  • facial volume loss
  • fine and moderate wrinkles
  • facial contour definition
  • overall facial rejuvenation

How the procedure is performed

The procedure lasts approximately 30–45 minutes.

  1. Facial evaluation
  2. Disinfection of the treatment area
  3. Product injection
  4. Light massage (in some cases)

👉 Local anesthesia can be used for additional comfort.

When do results appear

  • progressively within 4–8 weeks
  • maximum effect after several months
  • duration: up to 1–2 years

A few days before the procedure:

For safety:

  • avoid alcohol
  • avoid anti-inflammatory medications
  • avoid supplements that increase bleeding risk

Post-procedure instructions

For optimal results:

In the first 24–48 hours:

  • avoid excessive touching of the treated area
  • avoid intense exercise
  • avoid exposure to high temperatures (sauna, hot baths)

In some cases:

  • massage of the treated area is recommended, depending on the product used

Possible reactions

May include:

  • edema
  • redness
  • bruising
  • local sensitivity

👉 These are temporary and disappear within a few days.

Who is NOT a suitable candidate

The procedure is not recommended:

  • during pregnancy or breastfeeding
  • in active infections
  • in certain autoimmune diseases

Advantages of biostimulators

  • natural effect
  • long-lasting results
  • improve skin quality
  • do not excessively alter facial volume

Difference from hyaluronic acid

👉 Hyaluronic acid:

  • immediate volume
  • rapid effect

👉 Biostimulators:

  • gradual effect
  • collagen stimulation

❓ Frequently Asked Questions (FAQ)

When will I see results?

After several weeks.

Is the procedure painful?

Minimal, manageable discomfort.

How long do the effects last?

Up to 1–2 years.

How many sessions are needed?

Usually 1–3 sessions.

When to choose biostimulators

They are suitable if:

  • you want natural results
  • you are dealing with skin laxity
  • you want improved skin quality

📞 Schedule your evaluation

For the correct choice of treatment type and appropriate product:

👉 Schedule a consultation and personalized treatment plan.

Also Read

Related Articles

A single injection for cholesterol — from dreams to first human results
Useful information

A single injection for cholesterol — from dreams to first human results

A Phase 1 trial published in the New England Journal of Medicine (November 2025) brings remarkable results: a single infusion of CTX310, a CRISPR-Cas9 therapy developed by Cleveland Clinic and CRISPR Therapeutics, reduced LDL cholesterol by up to 49% and triglycerides by up to 55% in patients with refractory dyslipidemia — without serious adverse events. The mechanism is unique: instead of blocking a protein or interfering with its mRNA, CTX310 permanently edits the ANGPTL3 gene in hepatic cells, mimicking a natural mutation associated with reduced cardiovascular risk throughout life. The therapy is currently in Phase 1b clinical stage, with updates expected in the second half of 2026. It is not approved and does not replace current treatments. Read the full article for clinical context, comparison with statins and PCSK9 inhibitors, and what these data mean for patients. Medical Disclaimer This article presents results from a Phase 1 clinical trial in an early-stage research phase. The therapy described is not approved and is not available as standard treatment. The information is for educational purposes only. Consult your physician for any medical decision.

June 1, 2026Andra-Elena Balcangiu-Stroescu

Ready to schedule?

Book an appointment online or call us directly.

+40 747 777 107